|Day Low/High||3.73 / 3.96|
|52 Wk Low/High||3.24 / 13.80|
BioEurope 2015, EU Advanced Therapies Investor Day & Berlin Dialogue
ARM is the Preeminent Global Advocate for the Advancement of Regenerative Medicine
PLX-R18 for Use in Acute Radiation Syndrome (ARS) is Being Developed Under the Animal Rule Regulatory Pathway With the NIAID's Support
IATI Is the Largest Umbrella Organization for Israel's High Tech and Life Science Industries
Addresses Indications Including Peripheral Artery Disease for Which PLX Cells are Currently in Clinical Trials; Reinforces Company's Leadership Position in Large-Scale Manufacturing of Cell Therapies
Safety Clearance is Another Step Towards the Start of Phase II CLI Trial Via Japan's Accelerated Approval Pathway
Pluristem Also Presented Plans to Develop Accelerated Clinical Programs for PLX Cells in Ischemic Stroke, Muscle Wasting and Hip Fracture
Raymond James analyst Reni Benjamin says positive news may be ahead for these companies.
Fate Therapeutics (FATE) is developing several small molecules which modulate umbilical cord stem cells.
Study Results Published in Peer-Reviewed Scientific Journal
Phase I Trial of PLX-PAD Cells Underway in Australia for Pulmonary Arterial Hypertension
Company Fortifies IP Assets in Important Markets
Pluristem is Targeting Critical Limb Ischemia as the First Indication for Initial Marketing Authorization, Potentially Substantially Shortening the Time to Market of PLX Cells Via the Adaptive Pathways
Pluristem Completes Successful Meeting With PMDA and Satisfies Critical Prerequisite for Initiation of Clinical Study Targeting Fast-Track Approval in Japan
Patent Also Addresses Pluristem's Three Dimensional Culturing Technology
Company Targeting Accelerated Regulatory Pathways to Reduce PLX-PAD's Time to Market
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.